Retatrutide 30mg

Retatrutide (LY3437943) is an experimental triple hormone receptor agonist currently under development by Eli Lilly and Company. This novel compound is classified as a “triple-G” agonist because it simultaneously targets three distinct metabolic pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. [1, 2, 3, 4]

Important Compliance Notice: Retatrutide is not FDA-approved and is currently in Phase 3 clinical trials. Under federal law, it is not approved for human consumption, cannot be legally prescribed or compounded, and is strictly restricted to in vitro laboratory research and educational evaluation.